Aurora Cannabis announced on February 11 2026 that it broadened its medical‑cannabis lineup in Australia and New Zealand, adding four resin cartridges in Australia and two THC flower products in New Zealand.
The Australian launches include Chemango™ Kush, Cosmic Cream™, Lunar Express™ and Soul Train Haze™, while the New Zealand releases feature Big Wave™, Night Ride™ and the balanced strain Half Moon™ slated for Q1 FY27.
The new products are derived from Aurora’s proprietary genetics and are manufactured in its EU‑GMP and TGA‑GMP certified facilities in Canada, ensuring consistent quality and regulatory compliance.
This expansion targets two of Aurora’s largest international medical markets, reinforcing its medical‑first strategy and focus on high‑margin products. The company has been shifting away from lower‑margin Canadian consumer markets toward international medical sales, as reflected in its Q3 FY2026 results.
In Q3 FY2026 Aurora reported net revenue of $94.2 million, up 7% year‑over‑year, with global medical cannabis revenue of $76.2 million, up 12% year‑over‑year. Adjusted EBITDA was $18.5 million. The company reaffirmed full‑year FY2026 guidance for global medical cannabis net revenue of $269 million to $281 million and adjusted EBITDA of $52 million to $57 million. The new product launches are expected to contribute to continued premium pricing and margin expansion.
Investors expressed concerns about dilution following the announcement of an at‑market offering program, which coincided with the Q3 FY2026 earnings release.
Stanley Sack, Interim Managing Director of MedReleaf Australia, emphasized that Australia and New Zealand remain top priorities for Aurora, noting the importance of delivering high‑quality, diversified product formats to support prescribers. Miguel Martin, Executive Chairman and CEO, highlighted that Aurora’s focus on medical cannabis is anchored by investments in key markets, world‑class cultivation, GMP manufacturing, and regulatory expertise, reinforcing confidence in the company’s future.
Australia and New Zealand represent significant medical cannabis markets, and Aurora’s expansion aligns with its strategy to capture premium pricing in consolidated markets where GMP certification creates a competitive moat.
The launch of these new products positions Aurora to deepen its presence in Australia and New Zealand, potentially boosting revenue and reinforcing its medical‑first business model while the company continues to focus on high‑margin international growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.